Supplemental Data

Files in this Data Supplement:

• Supplemental Figure 1 - (SupplementalFig1.pdf; 119 KB) Cellular localization of ANXA1-WT-EGFP and ANXA1-S²⁷/A mutant in TtT/GF cells. Panel A: unstimulated cells transfected with the empty plasmid EGFP, ANXA1 WT-EGFP, or ANXA1-S²⁷/A-EGFP. Cells were fixed and stained with rhodamine-phalloidin. Merged images represent the EGFP-phalloidin. Panel B represent the cells stimulated with LPS (100 ng/ml, 5 minutes). All the images were collected at similar exposure time. All image files were processed for presentation using Image Pro plus software (Media Cybernetics) and imported directly in Power Point in publication format.
• Supplemental Figure 2 - (SupplementalFig2.pdf; 13 KB) Diagram of the different lipidation pathways and the pharmacological inhibitors used in the present study.

• Supplemental Figure 3 - (SupplementalFig3.pdf; 15 KB) ANXA1 consensus sequences for lipidation (Motif Scan and 3D-PSSM programs).
• Supplemental Figure 4 - (SupplemetalFig4.pdf; 18 KB) Lovastatin inhibits the access of LPS induced phosphorylated ANXA1 on the cell surface.FACS analysis of ANXA1-S²⁷-PO₄ expression after lovastatin treatment (10 μM, 16 hours). Cells were pretreated with lovastatin (lova) or lovastatin and mevalonic acid (Mev, 10 μM), lovastatin and FPP (5 μM), lovastatin and GGPP (5 μM), lovastatin and cholesterol (ch, 200 μM) followed by 5 min of LPS stimulation. Cells were harvested and further processed as reported in materials and method.